Exploring the Impact of Viking Therapeutics vs. Eli Lilly and Novo Nordisk in the Weight-Loss Drug Market
Why investors are excited about Viking Therapeutics
Some Wall Street analysts project that the market for weight loss drugs could reach or even top $100 billion by 2030. This expectation has helped fuel massive gains for Lilly and Novo Nordisk. Both pharma stocks are up more than 250% over the last three years.
How Viking Therapeutics, Eli Lilly, and Novo Nordisk compare
In most respects, Viking Therapeutics doesn't measure up well against Lilly and Novo Nordisk. The company doesn't have any approved products on the market and therefore isn't generating any sales. Meanwhile, Lilly and Novo Nordisk are giant drugmakers with multiple blockbuster products on the market.
Is Viking Therapeutics stock a better buy?
Risk-averse investors probably will still find Lilly and Novo Nordisk more attractive picks than Viking. However, Viking Therapeutics looks like the better choice for aggressive investors due to its growth potential and pipeline prospects.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.